Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | PACE: ctDNA landscape after CDK4/6 inhibitor progression for metastatic HR+/HER2- breast cancer

Rinath Jeselsohn • 19 Sep 2025
VJOncoAlert Journal Club
Breast Cancer

In this latest episode of the VJOncoAlert Journal Club, Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MD, discusses findings from the PACE trial (NCT03147287) analyzing circulating tumor DNA (ctDNA) dynamics in patients with HR+/HER2- metastatic breast cancer progressing on endocrine therapy plus CDK4/6 inhibition. Frequent alterations included ESR1, TP53, and PIK3CA mutations, with several variants linked to shorter progression-free survival. Longitudinal profiling showed enrichment of resistance-associated mutations at progression, highlighting the potential of ctDNA biomarkers to guide post-CDK4/6 inhibitor treatment strategies.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals